Program
Autologous Anti-CD7 CAR T Cells PA3-17
Its studies are mostly in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Scleroderma, Systemic · Lymphoma, led by PersonGen BioTherapeutics (Suzhou).
Drug pageAutologous Anti-CD7 CAR T Cells PA3-17: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PersonGen BioTherapeutics (Suzhou) | 63 open or running | phase 2since Sep 16, 2025 | Jul 14, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2020First study: phase 1 study in LymphomaFirst studyNCT04480788 · 9 enrolled · China
- Mar 3, 2021No phase study in Precursor T-Cell Lymphoblastic Leukemia-LymphomaNCT04785833 · 20 enrolled · China
- Dec 24, 2021Phase 1 study in CD7-positive Relapsed/Refractory Lymphoid Hematologic MalignanciesNCT05170568 · 22 enrolled · China
- Feb 27, 2025No phase study in Systemic Sclerosis - 2013 ACR/EULAR Classification CriteriaNCT06871644 · 18 planned · China
- Sep 16, 2025Phase 2 study in CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/LymphomaNCT07188610 · 100 planned · China
- May 28, 2026Phase 1 study in CD7+ T-ALL/LBLNCT07623681 · 12 planned · China
TargetBeta
“A preparation of autologous T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, ”NCIt, by rule
Other programs on CD7
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-CD7 CAR-T Cells RD13-02rule | nanjing-bioheng-biotech-co-ltd | early phase 1 | 1 |
| UTAA07rule | PersonGen BioTherapeutics (Suzhou) | early phase 1 | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07623681CD7+ T-ALL/LBL · China | 1 | Not yet recruiting | Jun 30, 2026 | 12 |
| NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma · China | 2 | Recruiting | Oct 1, 2026 | 100 |
| NCT06871644Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria · China | – | Not yet recruiting | Mar 31, 2026 | 18 |
| NCT05170568CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies · China | 1 | UNKNOWN | Dec 1, 2022 | 22 |
| NCT04785833Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · China | – | UNKNOWN | Apr 30, 2022 | 20 |
| NCT04480788Lymphoma · China | 1 | UNKNOWN | Aug 1, 2022 | 9 |
How it is read
Names in the registry
- “T cell injection targeting CD7 chimeric antigen receptor”, 6 entries
Conditions, from the studies’ own filings
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, 2 studies
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 study
- Scleroderma, Systemic, 1 study
- Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.